A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis Clinical Trial

Official title:

A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05265910
• Other study ID #: 21-960-0004
• Status: Completed
• Phase: Phase 4
• Start date: December 14, 2021
• Est. completion date: April 23, 2022

Study information

• Verified date: March 2022
• Source: Andover Research Eye Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: April 23, 2022
• Est. primary completion date: April 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Each subject must:

1. Be at least 18 years of age at Visit 1 of either gender and any race;

2. Provide written informed consent and sign the HIPAA form;

3. Be willing and able to follow all instructions and attend all study visits;

4. Have a history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, and/or tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the last 24 months;

5. Be able and willing to avoid all disallowed medications for the appropriate washout period and during the study (see exclusion 6);

6. Be able and willing to discontinue wearing contact lenses for at least 72 hours prior to Visit 1 and during the study trial period;

7. (for females capable of becoming pregnant) agree to have urine pregnancy testing performed at screening (must be negative) and exit visit; must not be lactating; and must agree to use a medically acceptable form of birth control throughout the study duration. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);

8. Have a calculated best-corrected visual acuity of 0.7 logMAR or better in each eye as measured using an ETDRS chart;

9. Have a positive bilateral post-CAC reaction (defined as having scores of =2 ocular itching and =2 conjunctival redness) within 10 (±2) minutes of instillation of the last titration of allergen at Visit 1;

10. Have a positive bilateral post-CAC reaction (defined as having scores of =2 ocular itching and =2 conjunctival redness) for at least two out of the first three time points following the challenge at Visit 2.

Exclusion Criteria:

Each subject must not:

1. Have known contraindications or sensitivities to the use of the investigational product or any of its components; 2. Have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium, history of corneal transplantation or a diagnosis of dry eye); 3. Have had ocular surgical intervention within three (3) months prior to Visit 1 or during the study and/or a history of refractive surgery within the past six (6) months; 4. Have a known history of retinal detachment, diabetic retinopathy, or active retinal disease; 5. Have the presence of an active ocular infection (bacterial, viral, or fungal) or positive history of an ocular herpetic infection at any visit; 6. Use any of the following disallowed medications during the period indicated prior to Visit 1 and during the study: 7 Days

• systemic or ocular H1-antihistamine, H1-antihistamine/mast cell stabilizers, H1-antihistamine-vasoconstrictor drug combinations;

• decongestants;

• monoamine oxidase inhibitors

• all other topical ophthalmic preparations (including artificial tears)

• lid scrubs;

• topical prostaglandins or prostaglandin derivatives

• ocular, topical, or systemic nonsteroidal anti-inflammatory drugs (NSAIDs, including baby aspirin (81 mg)) 14 Days

• inhaled, ocular, topical, or systemic corticosteroids or mast cell stabilizers; 45 Days

• depo-corticosteroids; Note: Currently marketed over-the-counter anti-allergy eye drops (i.e. anti-histamine/vasoconstrictor combination products such as Visine®-A®) may be administered to subjects by trained study personnel at the end of Visits 1, 2 and 4b after all evaluations are completed.

7. Have any significant illness (e.g. any autoimmune disease requiring therapy, severe cardiovascular disease [including arrhythmias] the investigator feels could be expected to interfere with the subject's health or with the study parameters and/or put the subject at any unnecessary risk (includes but is not limited to: poorly controlled hypertension or poorly controlled diabetes, a history of status asthmaticus, organ transplants, a known history of persistent moderate or severe asthma, or a known history of moderate to severe allergic asthmatic reactions to any of the study allergens; 8. Have received allergy immunotherapy within the last 2 years; 9. Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the start of Visits 1, 2, or 3 (defined as the presence of any itching or >1 [greater than 1] redness in any vessel bed); 10. Have a history of glaucoma; 11. Have planned surgery (ocular or systemic) during the trial period or within 30 days after; 12. Have used an investigational drug or medical device within 30 days of the study or be concurrently enrolled in another investigational product trial; 13. Be a female who is currently pregnant, planning a pregnancy, or lactating.

Related Conditions & MeSH terms

• Allergic Conjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic

Intervention

Drug:
• olopatadine hydrochloride ophthalmic solution 0.7%
Pataday® Once Daily Relief Extra Strength (eyedrop)
• loratadine 10 mg
Claritin® Tablets 24-Hour (tablet)
• Tears Naturale
Tears Naturale® II (eyedrop)
• Placebo
Placebo tablet (tablet)

Locations

Country	Name	City	State
United States	Andover Eye Associates	Andover	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Andover Research Eye Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ocular itching 3(±1) minutes post-CAC at Visit 3	Ocular itching evaluated by the subject at 3(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 3.	3(±1) minutes post-CAC on Day 1 (Visit 3)
Primary	Ocular itching 3(±1) minutes post-CAC at Visit 4b	Ocular itching evaluated by the subject at 3(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Vi sit 4b.	3(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Primary	Ocular itching 5(±1) minutes post-CAC at Visit 3	Ocular itching evaluated by the subject at 5(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 3.	5(±1) minutes post-CAC on Day 1 (Visit 3)
Primary	Ocular itching 5(±1) minutes post-CAC at Visit 4b	Ocular itching evaluated by the subject at 5(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 4b.	5(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Primary	Ocular itching 7(±1) minutes post-CAC at Visit 3	Ocular itching evaluated by the subject at 7(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Primary	Ocular itching 7(±1) minutes post-CAC at Visit 4b	Ocular itching evaluated by the subject at 7(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Conjunctival Redness	Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Conjunctival Redness	Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Conjunctival Redness	Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Ciliary Redness	Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Ciliary Redness	Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Ciliary Redness	Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Episcleral Redness	Episcleral redness evaluated by the investigator at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Episcleral Redness	Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Episcleral Redness	Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Chemosis	Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Chemosis	Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Chemosis	Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Eyelid Swelling	Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Eyelid Swelling	Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Eyelid Swelling	Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Tearing	Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Tearing	Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Tearing	Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Rhinorrhea	Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Rhinorrhea	Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Rhinorrhea	Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Nasal Pruritis	Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Nasal Pruritis	Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Nasal Pruritis	Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Ear or Palate Pruritis	Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Ear or Palate Pruritis	Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Ear or Palate Pruritis	Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Nasal Congestion	Nasal congestion evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Nasal Congestion	Nasal congestion evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 3.	15(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 3; Nasal Congestion	Nasal congestion evaluated by the subject 0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 3.	20(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Conjunctival Redness	Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Conjunctival Redness	Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Conjunctival Redness	Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Ciliary Redness	Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Ciliary Redness	Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Ciliary Redness	Ciliary redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Episcleral Redness	Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Episcleral Redness	Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Episcleral Redness	Episcleral redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Chemosis	Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Chemosis	Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Chemosis	Chemosis evaluated by the investigator (0-4 on the Ocular Chemosis scale with 4 being the worst, allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Eyelid Swelling	Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Eyelid Swelling	Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Eyelid Swelling	Eyelid swelling evaluated by the subject (0-3 on the Eyelid Swelling scale with 3 being the worst, not allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Tearing	Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Tearing	Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Tearing	Tearing evaluated by the subject (0-4 on the Tearing scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Rhinorrhea	Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Rhinorrhea	Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Rhinorrhea	Rhinorrhea evaluated by the subject (0-4 on the Rhinorrhea scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Nasal Pruritis	Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Nasal Pruritis	Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Nasal Pruritis	Nasal pruritis evaluated by the subject (0-4 on the Nasal Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Ear or Palate Pruritis	Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Ear or Palate Pruritis	Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Ear or Palate Pruritis	Ear or palate pruritis evaluated by the subject (0-4 on the Ear or Palate Pruritis scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 4b; Nasal Congestion	Nasal congestion pruritis evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	7(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 4b; Nasal Congestion	Nasal congestion pruritis evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	15(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Secondary	Secondary Efficacy Measures 20(±1) minutes post-CAC at Visit 4b; Nasal Congestion	Nasal congestion pruritis evaluated by the subject (0-4 on the Nasal Congestion scale with 4 being the worst, not allowing half unit increments) at Visit 4b.	20(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)